Top 10 Takeaways from Immuno-Oncology in 2025

Top 10 Takeaways from Immuno-Oncology in 2025

A comprehensive guide to the year's most transformative advances in cancer immunotherapy

2025 has been a landmark year for cancer immunotherapy. From breakthrough cell therapies to artificial intelligence changing how we predict treatment outcomes, the field has delivered transformative advances. Whether you're a clinician keeping current or someone interested in cancer research, here are the key developments from 2025 that matter most.

1Cell Therapies Get Smarter and More Accessible

CAR-T cell therapy continues evolving beyond blood cancers. New dual-target CAR-T approaches showed impressive results in brain tumors (glioblastoma), with about two-thirds of patients experiencing tumor shrinkage. Manufacturing has improved dramatically—the field is moving toward "off-the-shelf" versions using donor cells rather than requiring weeks-long patient-specific production.

Tumor-infiltrating lymphocyte (TIL) therapy marked a major milestone this year. Lifileucel became the first approved TIL therapy for solid tumors, specifically advanced melanoma. Five-year follow-up showed median survival over 60 months. What's exciting: TIL therapy also worked in hard-to-treat gastrointestinal cancers (pancreas, colon, bile duct) when combined with pembrolizumab.

New cell therapy options emerged too. CAR-NK cells (using natural killer cells instead of T cells) showed promise with fewer side effects, though they still have durability challenges. Multiple myeloma patients benefited from newer CAR-T approaches with better tolerability profiles.

💡 Why It Matters

Patients who've exhausted standard treatments now have more options, and faster manufacturing means less waiting time.

2T-Cell Receptor Therapies Enter Solid Tumors

After the FDA approved the first TCR therapy (afamitresgene) for synovial sarcoma in 2024, 2025 brought next-generation versions targeting PRAME, a protein found in multiple solid cancers including melanoma and ovarian cancer.

TCR therapies work differently than CAR-T: they recognize antigens hidden inside cancer cells rather than on the surface. This means they can target cancers that "hide" from conventional immunotherapy.

💡 Why It Matters

Solid tumors that lacked good treatment options may finally have viable alternatives.

3Bispecific Antibodies Become Mainstream

Bispecific antibodies—molecules that simultaneously bind to two different targets—have transitioned from experimental to routine therapy. The market is projected to reach $40 Billion. These drugs are manufactured at scale and available off-the-shelf, unlike cell therapies requiring customization.

Key approvals in 2025 include tarlatamab for small cell lung cancer (reducing death risk by 40%) and epcoritamab for lymphoma. These work by bringing immune cells directly to cancer cells, creating a precise "kill signal."

💡 Why It Matters

Bispecific antibodies offer a middle ground—more powerful than standard antibodies but far simpler and faster than engineered cell therapies.

4mRNA Cancer Vaccines Are Almost Here

Personalized mRNA cancer vaccines combined with pembrolizumab cut melanoma recurrence risk in half 44% Reduction after surgery. The market is projected to hit $5-7 Billion by 2030, with first approvals expected in late 2026 or 2027.

Beyond personalized vaccines, researchers discovered something surprising: COVID-19 mRNA vaccines appeared to boost cancer immunotherapy responses in some patients. This led to development of "universal" cancer vaccines designed to broadly activate the immune system rather than target specific tumors.

The NHS in the UK began enrolling head and neck cancer patients in mRNA vaccine trials, expanding beyond melanoma and lung cancer.

💡 Why It Matters

mRNA vaccines could complement checkpoint inhibitors, potentially helping patients who don't respond to immunotherapy alone.

5AI Now Predicts Who Will Respond to Immunotherapy

Artificial intelligence has moved from research labs into clinical practice. A model called SCORPIO predicts immunotherapy response with 72-76% Accuracy using just routine blood tests and basic clinical information—matching or beating tissue biopsies.

AI tools like Lunit's SCOPE IO examine immune infiltration patterns in tumors from imaging studies, identifying which patients benefit most from nivolumab plus ipilimumab (response rates: 60.5% "hot" vs 23.2% "cold").

An NCI-developed model called HistoTME examines the tumor microenvironment to predict treatment responses. Machine learning also predicts which patients will develop severe immune-related side effects, helping doctors manage toxicity proactively.

💡 Why It Matters

AI-guided selection could spare patients from ineffective treatments and identify those most likely to benefit.

6New Immune Checkpoints Beyond PD-1

While PD-1/PD-L1 blockade remains foundational, 2025 validated next-generation targets. LAG-3 showed promise when combined with nivolumab—better outcomes than PD-1 alone. TIGIT blockade combined with PD-L1 inhibition delivered durable responses in preclinical studies.

Scientists discovered that multiple checkpoints (PD-1, LAG-3, TIGIT, CTLA-4, TIM-3) are often simultaneously expressed on the same tumor-fighting cells. This explains why combining checkpoint inhibitors works better than single agents—blocking multiple "off switches" on immune cells.

💡 Why It Matters

Rational combinations targeting multiple checkpoints could improve response rates in cancers resistant to PD-1 inhibitors alone.

7Pre-Surgery Immunotherapy Becomes Standard Care

Giving immunotherapy before surgery (neoadjuvant) has shifted from experimental to routine across multiple cancers. The logic is sound: the tumor is present to educate immune cells, and treatment continues even after surgery removes the tumor.

In breast cancer, scientists found that specific immune cells (lipid-associated macrophages) predict who will relapse after pre-surgery immunotherapy, and these cells can be detected in blood samples.

Head and neck cancer patients receiving pre-surgery pembrolizumab had Double the Disease-Free Survival compared to surgery alone. NSCLC patients receiving pembrolizumab plus lenvatinib before surgery had 33% Complete Response.

💡 Why It Matters

Earlier immunotherapy means better cure rates and potential to reduce or avoid chemotherapy in some patients.

8Blood Tests Now Monitor Immunotherapy Response

Circulating tumor DNA (ctDNA) tests measure cancer DNA fragments in blood. A new clinical trial called BR.36 uses ctDNA measurements two weeks after starting immunotherapy to decide who needs treatment intensification.

In 136 patients monitored intensively, ctDNA showed a remarkable pattern: patients with complete clearance of tumor DNA had excellent outcomes, while those with persistent ctDNA frequently progressed. Three-week ctDNA changes predicted success or failure—before imaging showed anything.

ctDNA tests also distinguish true progression from pseudoprogression (temporary tumor growth before response), addressing a persistent clinical headache.

💡 Why It Matters

ctDNA offers earlier signals of treatment success or failure, enabling faster treatment adjustments rather than waiting for imaging.

9Why Immunotherapy Fails—and How to Fix It

Researchers made surprising discoveries about immunotherapy resistance. One Nature study revealed that cancer-induced nerve injury creates a chronically immunosuppressed environment—blocking IL-6 signaling reversed this.

Northwestern scientists identified USP22 as a marker of checkpoint inhibitor resistance present in nearly all resistant tumors. Blocking this protein plus combining checkpoint inhibitors might overcome resistance.

At ESMO 2025, several novel strategies showed promise:

• GDF-15 blocking (visugromab) achieved 61.5% Response Rate in resistant melanoma
• mRNA encoding immune antigens (mRNA-4359) elicited responses in heavily treated patients
• VISTA blockade (solnerstotug) plus cemiplimab achieved 14% Response Rate in checkpoint inhibitor-resistant tumors

💡 Why It Matters

Understanding why immunotherapy fails opens doors to rescue therapies for patients thought "immunotherapy resistant."

10Combination Immunotherapy Wins in Hard-to-Treat Cancers

A landmark trial (STELLAR-303) achieved something previously thought impossible: immunotherapy benefit in microsatellite-stable colorectal cancer—the 96% of patients typically resistant. Combining zanzalintinib (blocks multiple pathways) plus atezolizumab (PD-L1 inhibitor) added +2 Months Survival and reduced Death Risk by 20%.

FDA approved nivolumab plus ipilimumab for advanced liver cancer, with 36% Response Rates versus 13% for targeted therapy. This combination also prevented kidney cancer recurrence after surgery.

A new drug called NP-G2-044 overcame both primary resistance and resistance that develops over time, working across 7 different tumor types with 21% Response Rate and responses lasting up to 19 months.

💡 Why It Matters

Rational combinations targeting both tumor pathways and immune checkpoints are expanding who can benefit from immunotherapy.

🎯 The Big Picture: Where Immunotherapy is Heading

2025 demonstrated that immunotherapy is evolving beyond single-agent checkpoint inhibitors. The field is moving toward:

Personalized approaches — using AI and biomarkers to select the right therapy for each patient

Combination strategies — that target multiple pathways simultaneously

Earlier treatment — (pre-surgery) to maximize cure potential

Accessible therapies — (off-the-shelf bispecific antibodies and cell therapies) reaching more patients faster

Real-time monitoring — using blood tests rather than waiting for imaging

⚠️ The Reality Check: The challenges remain real—global access disparities, managing side effects, and manufacturing capacity for cell therapies. But the trajectory is clear: immuno-oncology is becoming more precise, more effective, and more accessible.

🚀 Looking Ahead to 2026

By 2026, expect more mRNA vaccine approvals, expanded use of pre-surgery immunotherapy across additional cancers, and AI biomarkers becoming routine in treatment planning. The next era of cancer care is arriving. The convergence of mechanistic understanding, technological sophistication, and clinical wisdom is delivering unprecedented results. For patients, for clinicians, and for the entire field of oncology—2025 was transformative.

This review synthesizes highlights from ESMO Congress 2025, ASCO Annual Meeting 2025, and SITC's 40th Annual Meeting, along with publications from Nature, The Lancet, and major cancer centers.

Oncology Updates